Article
Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR-targeted therapy response in colorectal cancer.
Cancer letters - 1 Oct 2021
Li Weiwei, Ma Yiming, He Longmei, Li Hongwei, Chu Yi, Jiang Zheng, Zhao Xinhua, Nie Yongzhan, Wang Xishan, Wang Hongying
Abstract excerpt
The Bcl-2 homolog Bcl-xL is emerging as a key factor in tumorigenesis due to its prominent pro-survival and cell death-independent functions. However, the regulation of Bcl-xL by microenvironment and its implication in cancer therapy of colorectal carcinoma (CRC) are unclear. Here, we demonstrated that Bcl-xL expression was positively associated with protease-activated receptor 2 (PAR2) in CRC. Activation of PAR2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.